Disease · EFO_0008008

lower urinary tract symptom

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lower urinary tract symptom. Diseases, record EFO_0008008. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008008

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lower urinary tract symptom; Open Targets
Open Targets ID: EFO_0008008; Open Targets
MeSH: D059411; MeSH
NCI Thesaurus: C94773; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 18 of its 50 drugs, from ClinicalTrials.gov; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAMSULOSIN	CHEMBL836	Small molecule	Phase 3	ClinicalTrials.gov	15	15	14	Drugs and targets
TADALAFIL	CHEMBL779	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
TAMSULOSIN HYDROCHLORIDE	CHEMBL1200914	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ALFUZOSIN	CHEMBL709	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
MIRABEGRON	CHEMBL2095212	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
SILODOSIN	CHEMBL24778	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
SOLIFENACIN SUCCINATE	CHEMBL1200803	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
SOLIFENACIN	CHEMBL1734	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEGARELIX	CHEMBL415606	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	7	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	7	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1d adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	6	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	6	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Phase 3	https://conductscience.org/library/genes/2798	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	5	Muscarinic acetylcholine receptor M2 antagonist	Phase 3	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	5	Muscarinic acetylcholine receptor M3 antagonist	Phase 3	https://conductscience.org/library/genes/1131	Drugs and targets
CALCRL	Calcitonin gene-related peptide type 1 receptor	4	Calcitonin gene-related peptide type 1 receptor antagonist	Unknown	https://conductscience.org/library/genes/10203	Drugs and targets
CALCA	Calcitonin gene-related peptide	3	Calcitonin gene-related peptide antagonist; Calcitonin gene-related peptide inhibitor	Unknown	https://conductscience.org/library/genes/796	Drugs and targets
CALCB	Calcitonin gene-related peptide	3	Calcitonin gene-related peptide antagonist; Calcitonin gene-related peptide inhibitor	Unknown	https://conductscience.org/library/genes/797	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	3	Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials64

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01018511	Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms	Phase 3	1,334	2015-12-17	Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms	SOLIFENACIN SUCCINATE, TAMSULOSIN HYDROCHLORIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01021332	Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms	Phase 3	1,067	2016-01-22	Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia	SOLIFENACIN SUCCINATE, TAMSULOSIN HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00384930	Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia	Phase 2/3	1,058	2009-08-19	Benign Prostatic Hyperplasia	TADALAFIL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01078545	Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)		729	2012-01-06	Advanced Prostate Cancer, Lower Urinary Tract Symptoms	LEUPROLIDE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01139762	A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms	Phase 3	696	2013-02-27	Benign Prostatic Hyperplasia, Enlarged Prostate	FINASTERIDE, TADALAFIL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01726270	An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms	Phase 2	689	2020-03-27	Lower Urinary Tract Symptoms	TAMSULOSIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00284518	Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia	Phase 2	380	2012-12-17	Benign Prostatic Hyperplasia	ONABOTULINUMTOXINA	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00827242	Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily	Phase 3	325	2010-11-17	Benign Prostatic Hyperplasia	TADALAFIL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00833248	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Phase 3	246	2012-09-27	Prostate Cancer	BICALUTAMIDE, DEGARELIX, GOSERELIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00507455	Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction	Phase 2	222	2014-08-06	Lower Urinary Tract Symptoms, Bladder Outlet Obstruction	SOLIFENACIN SUCCINATE, TAMSULOSIN HYDROCHLORIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 64

See all 64 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tadalafil vs Placebo: serious adverse events	2 of 161	0 of 164	325	NCT00827242	Trial comparisons
Degarelix 240 mg/80 mg vs Goserelin (3.6 mg) + Bicalutamide (50 mg): serious adverse events	7 of 181	0 of 64	245	NCT00833248	Trial comparisons
Study Group vs Control Group: serious adverse events	0 of 64	0 of 58	122	NCT01678313	Trial comparisons
Placebo, Then Alfuzosin vs Alfuzosin, Then Placebo: serious adverse events	1 of 36	1 of 38	74	NCT00893113	Trial comparisons
Degarelix 240 mg/80 mg vs Goserelin (3.6 mg) + Bicalutamide (50 mg): serious adverse events	0 of 27	1 of 13	40	NCT00831233	Trial comparisons
ARM 1: onaBoNT-A + Placebo vs ARM 2: Saline + Tamsulosin: deaths from any cause	0 of 9	0 of 12	21	NCT01589263	Trial comparisons
ARM 1: onaBoNT-A + Placebo vs ARM 2: Saline + Tamsulosin: serious adverse events	1 of 9	0 of 12	21	NCT01589263	Trial comparisons

Papers from its trials56

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28914703	RESULT	1	PubMed
28594764	RESULT	1	PubMed
28116468	RESULT	1	PubMed
27033958	RESULT	1	PubMed
26698878	RESULT	1	PubMed
26226555	RESULT	1	PubMed
26054658	RESULT	1	PubMed
24463669	RESULT	1	PubMed
24421434	RESULT	1	PubMed
24294288	RESULT	1	PubMed

1 to 10 of 56

See all 56 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008008

GET https://conductscience.org/api/diseases/v1/EFO_0008008/drugs?page=2

API reference For AI assistants